Form 8K Retension Pharmaceuticals For: 18 November
- Investing.com
Metrics to compare | RTSN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRTSNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −6.7x | 3.0x | −0.2x | |
PEG Ratio | - | −0.23 | 0.00 | |
Price/Book | −6.4x | 0.9x | 2.6x | |
Price / LTM Sales | - | 1.4x | 2.7x | |
Upside (Analyst Target) | 352.8% | 130.2% | 68.5% | |
Fair Value Upside | Unlock | 35.7% | 11.5% | Unlock |
Retension Pharmaceuticals, Inc. operates as a clinical -stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. It offers RTN -001, an oral, small molecule phosphodiesterase -5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling. The Company operates as a single operating and reportable segment focused on the development of treatments for hypertension and cardiovascular disease. The company was incorporated in 2023 and is headquartered in Falls Church, Virginia.